PURPOSE: The inter/intramolecular interactions between drugs (floxuridine, irinotecan) and excipients (copper gluconate, triethanolamine) in the dual-drug liposomal formulation CPX-1 were elucidated in order to identify the physicochemical properties that allow coordinated release of irinotecan and floxuridine and maintenance of the two agents at a fixed, synergistic 1:1 molar ratio. METHODS: Release of irinotecan and floxuridine from the liposomes was assessed using an in vitro-release assay. Fluorescence, Nuclear Magnetic Resonance spectroscopy (NMR) and UV-Vis were used to characterize the aggregation state of the drugs within the liposomes. RESULTS: Coordinated release of the drugs from liposomes was disrupted by removing copper gluconate. Approximately 45% of the total irinotecan was detectable in the copper-containing CPX-1 formulation by NMR, which decreased to 19% without copper present in the liposomal interior. Formation of higher order, NMR-silent aggregates was associated with slower and uncoordinated irinotecan release relative to floxuridine and loss of the synergistic drug/drug ratio. Solution spectroscopy and calorimetry revealed that while all formulation components were required to achieve the highest solubility of irinotecan, direct drug-excipient binding interactions were absent. CONCLUSIONS: Long-range interactions between irinotecan, floxuridine and excipients modulate the aggregation state of irinotecan, allowing for simultaneous release of both drugs from the liposomes.
PURPOSE: The inter/intramolecular interactions between drugs (floxuridine, irinotecan) and excipients (copper gluconate, triethanolamine) in the dual-drug liposomal formulation CPX-1 were elucidated in order to identify the physicochemical properties that allow coordinated release of irinotecan and floxuridine and maintenance of the two agents at a fixed, synergistic 1:1 molar ratio. METHODS: Release of irinotecan and floxuridine from the liposomes was assessed using an in vitro-release assay. Fluorescence, Nuclear Magnetic Resonance spectroscopy (NMR) and UV-Vis were used to characterize the aggregation state of the drugs within the liposomes. RESULTS: Coordinated release of the drugs from liposomes was disrupted by removing copper gluconate. Approximately 45% of the total irinotecan was detectable in the copper-containing CPX-1 formulation by NMR, which decreased to 19% without copper present in the liposomal interior. Formation of higher order, NMR-silent aggregates was associated with slower and uncoordinated irinotecan release relative to floxuridine and loss of the synergistic drug/drug ratio. Solution spectroscopy and calorimetry revealed that while all formulation components were required to achieve the highest solubility of irinotecan, direct drug-excipient binding interactions were absent. CONCLUSIONS: Long-range interactions between irinotecan, floxuridine and excipients modulate the aggregation state of irinotecan, allowing for simultaneous release of both drugs from the liposomes.
Authors: Troy O Harasym; Paul G Tardi; Natashia L Harasym; Pierrot Harvie; Sharon A Johnstone; Lawrence D Mayer Journal: Oncol Res Date: 2007 Impact factor: 5.574
Authors: Daryl C Drummond; Charles O Noble; Zexiong Guo; Keelung Hong; John W Park; Dmitri B Kirpotin Journal: Cancer Res Date: 2006-03-15 Impact factor: 12.701
Authors: Jeremy A Bartlett; Marcus Brewster; Paul Brown; Donna Cabral-Lilly; Celia N Cruz; Raymond David; W Mark Eickhoff; Sabine Haubenreisser; Abigail Jacobs; Frank Malinoski; Elaine Morefield; Ritu Nalubola; Robert K Prud'homme; Nakissa Sadrieh; Christie M Sayes; Hripsime Shahbazian; Nanda Subbarao; Lawrence Tamarkin; Katherine Tyner; Rajendra Uppoor; Margaret Whittaker-Caulk; William Zamboni Journal: AAPS J Date: 2014-11-25 Impact factor: 4.009
Authors: Rui Xue Zhang; Jason Li; Tian Zhang; Mohammad A Amini; Chunsheng He; Brian Lu; Taksim Ahmed; HoYin Lip; Andrew M Rauth; Xiao Yu Wu Journal: Acta Pharmacol Sin Date: 2018-04-26 Impact factor: 6.150